FDA Approved: DUOBRII — Original Application (Bausch Health US, LLC)

View source ↗

Summary

FDA approved Duobrí (halobetasol propionate and tazarotene) as a new fixed-dose topical combination for the treatment of plaque psoriasis in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Duobrii (halobetasol propionate and tazarotene)

Snippet

ORIG AP for DUOBRII (HALOBETASOL PROPIONATE AND TAZAROTENE)